口服锰对比剂与平扫MRI及钆贝葡胺在结直肠癌肝转移评估中的病灶可视化比较:一项随机交叉II期研究的集中评估
该研究由3名独立读片者以盲法集中分析既往随机交叉II期试验中20例已知或疑似肝转移患者的MRI,比较口服锰对比剂ACE-MBCA与平扫MRI及钆贝葡胺的病灶可视化能力。结果显示ACE-MBCA增强MRI在病灶边界显示和病灶对比上显著优于平扫MRI(P<0.001),检出病灶数更多,尤其<1 cm小病灶,且与钆贝葡胺可视化参数相当、无显著差异。
要点
- ACE-MBCA增强MRI的病灶边界显示和病灶对比评分显著优于平扫MRI(P<0.001)。
- ACE-MBCA较平扫MRI检出更多肝病灶(平均差0.4-0.8个,95%CI 0.04-1.52),尤其<1 cm小病灶。
- ACE-MBCA与钆贝葡胺在结直肠癌肝转移灶的可视化和检出方面表现相似、无显著差异。
核心结论
- 与平扫MRI相比,ACE-MBCA MRI可获得更优的病灶可视化和更多的检出肝病灶;ACE-MBCA与钆贝葡胺在结直肠癌肝转移灶的可视化和检出方面表现相似。
研究设计与样本
- 对既往完成的随机交叉II期临床试验的MRI进行盲法集中评估,纳入20例连续成年已知或疑似肝转移患者,均接受ACE-MBCA和钆贝葡胺两种对比剂。
关键影像表现/征象
- 3名读片者评估6种MRI扫描(两种对比剂的平扫、增强和联合MRI),主要结局为病灶边界显示(LBD)和病灶对比(LC)。
诊断标准与关键数值
- ACE-MBCA增强MRI较平扫MRI的LBD平均评分从1.8-2.3提高到2.4-2.9,LC评分从1.8-2.3提高到2.8-3.3,3名读片者均P<0.001。
- ACE-MBCA较平扫MRI检出更多病灶,所有读片者平均差0.4-0.8个(95%CI 0.04-1.52);<1 cm小病灶检出从2-6个提高到3-12个。
- ACE-MBCA增强后肝-病灶对比和对比噪声比显著更高。
- ACE-MBCA的所有可视化参数与钆贝葡胺相当,无显著差异。
临床应用与阅片要点
- ACE-MBCA增强MRI较平扫MRI可改善肝病灶边界显示、病灶对比和病灶检出,尤其对<1 cm小病灶。
- ACE-MBCA与钆贝葡胺在结直肠癌肝转移灶可视化和检出方面表现相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: The primary objective of this study was to evaluate the visualization capability of orally administered manganese chloride tetrahydrate (ACE-MBCA [Ascelia Pharma-manganese-based contrast agent, also referred to as Orviglance or CMC-001]), a novel liver-specific contrast agent developed by Ascelia Pharma, as a liver-specific MRI contrast agent compared with that of the unenhanced MRI for focal liver lesions in a properly blinded study design. The secondary objective was to compare the performance of ACE-MBCA with gadobenate dimeglumine.
MATERIALS AND METHODS: Three independent readers analyzed MRI examinations from a previously completed randomized crossover clinical trial in a blinded manner in a centralized setting. The study included 20 consecutive adult patients with known or suspected liver metastases, who received both ACE-MBCA and gadobenate dimeglumine. The readers evaluated 6 types of MRI scans (unenhanced, enhanced, and combined MRI for both contrast agents) with lesion visualization [lesion border delineation (LBD) and lesion contrast (LC)] as primary outcome. To maintain the blinded nature of the study, all statistical analyses were performed by an independent statistician who was not involved in the image reading process. Differences in primary outcomes were performed using 1-sided paired t tests at a significance level of 0.025 for both parameters. For secondary outcomes (ACE-MBCA enhanced MRI visualization, lesion detection, size measurements, reader confidence, quantitative parameters, and image quality were compared with that of the other scans), descriptive statistics and 95% confidence intervals were used to evaluate differences between categories in comparative analyses, without formal hypothesis testing for most secondary endpoints.
RESULTS: ACE-MBCA-enhanced MRI demonstrated statistically significant superior scoring over unenhanced MRI for visualizing focal liver lesions, with mean LBD scores improving from 1.8-2.3 to 2.4-2.9 and LC scores ranging from 1.8-2.3 to 2.8-3.3 across all 3 readers ( P < 0.001). Compared with unenhanced MRI, ACE-MBCA detected significantly more lesions across all readers (mean differences 0.4-0.8 lesions, 95% CI: 0.04-1.52), particularly for small lesions (<1 cm), where detection improved from 2-6 to 3-12 lesions. Liver-to-lesion contrast and contrast-to-noise ratios were also significantly higher after ACE-MBCA enhancement. All visualization parameters of ACE-MBCA were comparable to those of gadobenate dimeglumine, with no significant differences.
CONCLUSIONS: Compared with unenhanced MRI, ACE-MBCA MRI resulted in superior visualization and a greater number of detected liver lesions. ACE-MBCA and gadobenate dimeglumine performed similarly in the visualization and detection of colorectal liver metastases.
引用
- Brismar TB, Kartalis N, Hettiarachchige N, et al. Lesion Visualization of an Oral Manganese Contrast Agent Compared to Unenhanced MRI and Gadobenate Dimeglumine in Patients Undergoing Liver Magnetic Resonance Imaging for Evaluation of Colorectal Cancer Metastases: Centralized Assessment of a Randomized, Crossover, Phase II Study. Invest Radiol. 2025. PMID: 40193954. doi:10.1097/RLI.0000000000001184
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。